Rohit Loomba, MD, MHSc - Hope Is on the Horizon for Nonalcoholic Steatohepatitis: Leveraging the Power of Next Generation Monitoring and Pharmacotherapies

PeerView Gastroenterology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/RVV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hepatology discusses NAFLD and NASH as metabolic diseases and potential therapeutic targets for patients with the conditions. Upon completion of this activity, participants should be better able to: Describe the disease pathways and mechanisms that define NAFLD/NASH as metabolic diseases; Discuss the pathophysiology and role of GLP-1 as a therapeutic target in NAFLD/NASH and other metabolic conditions; Use noninvasive tests and biomarkers to monitor NAFLD/NASH disease progression; and Initiate early guideline-driven and pathway-driven management with available and emerging pharmacotherapies to delay NAFLD/NASH progression and improve outcomes for patients